CCA
CMMB

Catalyst Capital Advisors’s Chemomab Therapeutics CMMB Stock Holding History

Catalyst Capital Advisors’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8
Closed -$3K – 425
2019
Q1 		$3K Buy
+8
New +$4.05K ﹤0.01% 383

Other funds holding CMMB

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DG
Delek Group Herzliya, Israel $2.59B AUM 1.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Catalyst Capital Advisors's CMMB Position: Q2 2019 in Review

Catalyst Capital Advisors sold out of Chemomab Therapeutics (CMMB) in Q2 2019, closing a stake of 8 shares — an estimated $3K sold.

Catalyst Capital Advisors first reported a position in CMMB in Q1 2019 and held it in 1 quarter. The position peaked at $3K in Q1 2019. 9 funds tracked by Wall St. Rank hold CMMB as of Q2 2019.

  • Catalyst Capital Advisors reported no remaining Chemomab Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 8 Chemomab Therapeutics shares in Q2 2019, an estimated $3K.
  • Catalyst Capital Advisors first reported a position in Chemomab Therapeutics in Q1 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Chemomab Therapeutics position peaked at $3K in Q1 2019.
  • 9 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2019.

Based on Catalyst Capital Advisors's 13F filing for Q2 2019, filed 8 Aug 2019.